Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.9, Iss.2, 2008-02, pp. : 301-309

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: Efficacy and long-term safety in a single institution

By Brion Annie

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1697-1702

Springer Publishing Company

Access to resources Recommend Favorite

Liposomal daunorubicin + cytarabine effective in AML

Inpharma, Vol. 1, Iss. 1304, 2001-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Disposition of Liposomal Daunorubicin During Cotreatment with Cytarabine in Patients with Leukaemia

By Pea F.

Clinical Pharmacokinetics, Vol. 42, Iss. 9, 2003-01 ,pp. : 851-862

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and Safety of Intrathecal Liposomal Cytarabine in Children Aged <3 Years

By Peyrl Andreas

Clinical Pharmacokinetics, Vol. 48, Iss. 4, 2009-06 ,pp. : 265-271

Adis International

Access to resources Recommend Favorite

Epidemiology and management of cryptococcal meningitis: developments and challenges

By Pukkila-Worley Read Mylonakis Eleftherios

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 4, 2008-03 ,pp. : 551-560

Informa Healthcare

Access to resources Recommend Favorite